Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo

Cancer Research

Volumn 58, Issue 4, 1998, Pages 834-839

  Srikanth, Sampathkumar ^a   Kraft, Andrew S ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANDROGEN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYTOKINE RESPONSE MODIFIER A; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CELL DEATH; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; APOPTOSIS; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORCHIECTOMY; PROSTATIC NEOPLASMS; SERPINS; TRANSPLANTATION, HETEROLOGOUS; VIRAL PROTEINS;

EID: 0032520068     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Netto, G. J., and Humphrey, P. A. Molecular biological aspects of human prostatic carcinoma. Am. J. Clin. Pathol., 102: 57-64, 1994.
2. Ware, J. Prostate cancer progression. Am. J. Pathol., 145: 983-993, 1994.
3. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
4. Denmeade, R., Liu, X. S., and Isaacs, J. T. Role of programmed cell death during the progression and therapy of prostate cancer. Prostate, 28: 251-265, 1996.
5. Peehl, D. Oncogenes in prostate cancer. Cancer (Phila.), 71: 1159-1164, 1993.
6. Voeller, H. J., Wilding, G., and Gelmann, E. P. V-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol., 5: 209-216, 1991.
7. Isaacs, J. T., Lundmo, P. I., Berges, R., Martikainen, P., Kyprianou, N., and English, H. F. Androgen regulation of programmed cell death of normal and malignant prostatic cells. J. Androl., 13: 457-464, 1992.
8. Buttyan, R., Zakeri, Z., Lockshin, R., and Wolgemuth, D. Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol. Endocrinol., 2: 650-657, 1988.
9. Sells, S. F., Wood, D. P., Joshi-Barve, S., Muthukumar, S., Jacob, R. J., Crist, S., Humphreys, S., and Ragnekar, V. M. Commonality of gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ., 5: 457-466, 1994.
10. Martin, S. J., and Green, D. R. Protease activation during apoptosis: death by a thousand cuts? Cell, 82: 349-352, 1995.
11. White, E. Life, death and the pursuit of apoptosis. Genes Dev., 10: 1-15, 1996.
12. Itoh, N., and Nagata, S. A novel protein domain required for apoptosis. J. Biol. Chem., 268: 10932-10937, 1993.
13. Cohen, G. M. Caspases: the executioners of apoptosis. Biochem. J., 326: 1-16, 1996.
14. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. Human ICE/CED3 protease nomenclature. Cell, 87: 171, 1996.
15. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
16. Friesen, C., Herr, I., Krammer, H. P., and Debatin, K. M. Involvement of the CD95 (Apo-1/Fas) receptor ligand system in drug-induced apoptosis in leukemic cells. Nat. Med., 2: 574-578, 1996.
17. Muller, M., Strand, S., Hig, H., Heinemmann, E. M., Walczak, H., Hoffmann, W., Stremmel, W., Krammer, H. P., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 receptor ligand system and involves the activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.
18. Boldin, M. P., Gancharov, T. M., Goltsev, Y. V., and Wallach, D. Involvement of MACH, a novel Mort1/Fadd-Interacting protease in Fas/APO-1- and TNF receptorinduced cell death. Cell, 85: 803-815, 1996.
19. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R., Mann, M., Krammer, P. H., Peter, M. E., and Dixit, V. M. Caspase-8, a novel Fadd-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell, 85: 817-827, 1996.
20. Tewari, M., and Dixit, V. M. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus CrmA gene product. J. Biol. Chem., 270: 3255-3260, 1995.
21. Zhou, Q., Snipas, S., Orth, K., Muzio, M., Dixit, V. M., and Salvesen, G. S. Target protease specificity of the viral serpin CrmA. J. Biol. Chem., 272: 7797-7800, 1997.
22. Quan, L. T., Caputo, A., Bleackley, R. C., Pickup, D. J., and Salvesen, G. S. Granzyme B is inhibited by the cowpox virus serpin CrmA. J. Biol. Chem., 270: 10377-10379, 1996.
23. Beidler, D., Tewari, M., Friesen, P. D., Poirer, G., and Dixit, V. M. The baculovirus p35 protein inhibits Fas- and tumor necrosis factor-induced apoptosis. J. Biol. Chem., 270: 16526-16528, 1995.
24. Thome, M., Schneider, P., Hofmann, K., Fickenscev, H., Meinl, E., Neipel, F., Mattmann, C., Burns, K., Bodmer, J. L., Schroter, M., Scaffidi, C., Krammer, P. H., Peter, M. E., and Tschopp, J. Viral caspase-8-inhibitory proteins (VFLIPs) prevent apoptosis induced by death receptors. Nature (Lond.), 386: 517-521, 1997.
25. Reed, J. C. Bcl-2 and regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
26. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
27. Colombel, M., Symmons, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olson, C., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am. J. Pathol., 143: 390-400, 1993.
28. Raffo, A. J., Perlman, H., Chen, M-W., Day, M. L., Strietman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
29. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyer, S., Zeng, Z., Beidler, D. R., Poirer, G. G., Salvesen, G. S., and Dixit, V. M. Yama/cpp32, a mammalian homolog of ced-3, is a CrmA-inhibitable protease that cleaves the death substrate PARP. Cell, 81: 801-809, 1995.
30. Saeed, B., Zhang, H., and Ng, S. C. Apoptotic program is initiated but not completed in LNCaP cells in response to growth in charcoal stripped media. Prostate, 31: 145-152, 1997.
31. Frisch, S. M., Vuori, K., Kelaita, D., and Sicks, S. A role for jun N-terminal kinase in anoikis; suppression by bcl-2 and CrmA. J. Cell Biol., 135: 1377-1382, 1996.
32. Gagliardini, V., Femandez, P-A., Lee, R. K., Frexler, H. C., Rotello, R. J., Fishmann, M. C., and Yuan, J. Prevention of venebrate neuronal death by the CrmA gene. Science (Washington DC), 263: 826-828, 1994.
33. Suzuki, A., Matsuzawa, A., and Iguchi, T. Down-regulation of bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene, 13: 31-37, 1996.
34. Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. L., Barr, P. J., and Mountz, J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science (Washington DC), 263: 1759-1762, 1994.
35. Cascino, I., Fiucci, G., Papoff, G., and Ruberti, G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol., 154: 2706-2713, 1995.
36. Papoff, G., Cascino, I., Eramo, A., Starace, G., Lynch, D. H., and Ruberti, G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J. Immunol., 156: 4622-4630, 1996.
37. Renvoize, C., Roger, R., Moulian, N., Bertoglio, J., and Breard, J. Bcl-2 expression in target cells leads to functional inhibition of caspase-3 protease family in human NK and lymphokine-activated killer cell granule-mediated apoptosis. J. Immunol., 159: 126-134, 1997.
38. Janicke, R. U., Walker, P. A., Lin, X. Y., and Porter, A. G. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J., 15: 6969-6978, 1996.
39. Tan, X., Martin, S. J., Green, D. R., and Wang, J. Y. J. Degradation of retinoblastoma protein in TNF- and CD95-induced cell death. J. Biol. Chem., 272: 9613-9616, 1997.
40. Dou, Q. P., An, B., Antoku, K., and Johnson, D. E. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell. Biochem., 64: 586-594, 1997.
41. Anderson, P. Kinase cascades regulating entry into apoptosis. Microbiol. Mol. Biol. Rev., 61: 33-46, 1997.
42. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science (Washington DC), 270: 1326-1331, 1995.
43. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. Requirement for ceramideinitiated SAPK/JNK signaling in stress-induced apoptosis. Nature (Lond.), 380: 75-79, 1996.
44. Goillot, E., Raingeaud, J., Ranger, A., Tepper, R. I., Davis, R. J., Harlow, E., and Sanchez, I. MAPK-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA, 94: 3302-3307, 1997.
45. Juo, P., Kuo, C. J., Reynolds, S. E., Konz, R. F., Raingeaud, J., Davis, R. J., Biemann, H. P., and Blenis, J. Fas activation of the p38 mitogen-activated protein kinase signaling pathway requires ICE/CED-3 family proteases. Mol. Cell. Biol., 17: 24-35, 1997.
46. Lassignal-Johnson, N., Gardner, A., Diener, K., Lange-Carter, C., Gleavy, J., Jarpe, M., Minden, A., Karin, M., Zon, L., and Johnson, G. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase-induced cell death. J. Biol. Chem., 271: 3229-3237, 1996.